Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24370916 | 0.73 | HAVCR2 (0.38) | HAVCR2PDE2A | |
| SCHEMBL25848619 | 0.68 | ALDH1A1 (0.31) | — | |
| SCHEMBL24470101 | 0.68 | PDE2A (0.38) | HAVCR2PDE2A | |
| SCHEMBL25820356 | 0.68 | — | — | |
| SCHEMBL798669 | 0.68 | AHR (0.33) | — | |
| SCHEMBL12305595 | 0.67 | PDE2A (0.43) | PDE2A | |
| SCHEMBL25848618 | 0.64 | NOS3 (0.32) | — | |
| SCHEMBL18748604 | 0.62 | CHEK1 (0.33) | — | |
| SCHEMBL798670 | 0.62 | NAMPT (0.43) | — | |
| SCHEMBL27112109 | 0.61 | HAVCR2 (0.31) | HAVCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708369-B2 | Heteroaromatic compounds having activity against RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2023-07-25 | — | — | US | disclosed |
| US-11708369-B2 | Heteroaromatic compounds having activity against RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708369-B2 | Heteroaromatic compounds having activity against RSV | MAVS, ZC3HAV1, SARS1 | HAVCR2 11/4885PDE2A 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.